Singapore markets closed

Clinuvel Pharmaceuticals Limited (CUV.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
14.97+0.07 (+0.45%)
At close: 03:59PM AEST
Full screen
Previous close14.90
Open14.85
Bid0.00 x N/A
Ask0.00 x N/A
Day's range14.70 - 15.04
52-week range12.98 - 21.43
Volume8,410
Avg. volume6,392
Market capN/A
Beta (5Y monthly)0.94
PE ratio (TTM)31.85
EPS (TTM)0.47
Earnings date26 Aug 2024 - 30 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Clinuvel Pharmaceuticals Leads Three High Growth Companies With Significant Insider Ownership

    As global markets navigate through a period of relative calm with anticipation for upcoming earnings reports and key economic indicators, investors continue to assess the landscape for robust investment opportunities. In this environment, growth companies with high insider ownership can be particularly compelling, as substantial insider stakes often signal confidence in the company's future prospects from those who know it best.

  • GlobeNewswire

    Afamelanotide in fair-skinned Parkinson’s patients

    Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,

  • Simply Wall St.

    Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company

    Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...